Читать книгу Practical Cardiovascular Medicine - Elias B. Hanna - Страница 165

1 83. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318: 1730–7. β-Blockers reduce mortality 23% over long-term (6–24 months), not short-term follow-up.

2 84. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo- controlled trial. Lancet 2005; 366: 1622–32. COMMIT-CCS trial.

3 85. Bangalore S, Steg G, Deedwania P, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012; 308: 1340–9. REACH registry.

4 86. Puymirat E, Riant E, Aissaoui N, et al. Beta-blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ 2016;354:i4801. FAST MI registry: mortality benefit with beta-blockers up to 1 year after MI, not beyond that.

5 87. Goldberger JJ, Bonow RO, Cuffe M, et al. Effect of beta-blocker dose on survival after acute myocardial infarction. J Am Coll Cardiol 2015; 66: 1431–41.

6 88. CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN ran- domised trial. Lancet 2001; 357: 1385–90.

7 89. ISIS-4 Collaborative Group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669–85.

8 90. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115–22. GISSI-3 and ISIS-4 proved a mortal- ity reduction with early initiation of ACE-I in all STEMI patients (within 24 hours, for 6 weeks). SAVE trial proved a more drastic mortality reduction with captopril in MI patients with LV dysfunction (for 42 months).

9 91 Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992; 327(10):669–677.

10 92. Deedwania P, Kosiborod M, Barrett E, et al. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2008; 117: 1610–19.